-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa presents preclinical data on CCNE1 degrader MRT-55811 at AACR 2026

PUBT·04/20/2026 11:05:50
Listen to the news
Monte Rosa presents preclinical data on CCNE1 degrader MRT-55811 at AACR 2026
  • Monte Rosa Therapeutics disclosed new preclinical results for MRT-55811, an oral cyclin E1 molecular glue degrader aimed at CCNE1-amplified solid tumors.
  • Data will be presented April 21, 2026, at AACR Annual Meeting in an oral session.
  • Study readouts showed tumor regressions across multiple CCNE1-amplified models, supporting potential use as monotherapy in selected ovarian, breast, or gastric cancers.
  • Program showed higher selectivity with fewer off-target effects than clinical-stage CDK2 inhibitors, positioning it as a potential differentiated approach.
  • Monte Rosa expects to submit an IND for MRT-55811 later in 2026, setting up a potential move into clinical testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.